Furthermore, Hp-related galectin-3 connected with MetS may play a role in the pathophysiology of MetS-related NAFLD and its extrahepatic complications, including chronic kidney, cardiovascular, and brain disorders; the number of galectin-3 positive liver cells is associated with NAFLD severity; galectin-3 binding protein is a potential marker of disease; and galectin-3 inhibitors may exhibit potential efficacy in advanced fibrosis/cirrhosis due to NASH. This evidence concerns the gene HP and metabolic dysfunction-associated steatohepatitis.